| Literature DB >> 31849550 |
Arman Sadatsharifi1, Mohammad-Ali Davarpanah2, Soha Namazi3, Shaghayegh Mottaghi1, Laleh Mahmoudi1.
Abstract
INTRODUCTION: Widespread inappropriate antibiotic prescribing by healthcare professionals in the hospital setting is a great concern that may cause many undesirable consequences. Adherences to antibiotic guidelines have proven to be a simple and effective intervention to guide the choice of appropriate empiric antibiotic regimens and reduce the unnecessary variations in the practice among practitioners. The objective of this study was to evaluate the prescription patterns of empiric antibiotic therapy in relation to treatment guidelines and the economic burden of discordance with guidelines in a major referral Iranian university hospital.Entities:
Keywords: consumption; economic burden; hospital; inappropriate antibiotic usage
Year: 2019 PMID: 31849550 PMCID: PMC6913765 DOI: 10.2147/RMHP.S222200
Source DB: PubMed Journal: Risk Manag Healthc Policy ISSN: 1179-1594
Figure 1Assessment criteria for the evaluation of the quality of antibiotics prescription.
Demographic And Clinical Data Of The Patients (n=229)
| Variable | n(%) Or Mean ± SD |
|---|---|
| Sex | |
| Male | 115(50.2) |
| Female | 114(49.8) |
| Age (years) | 56.42 ± 19.54 |
| BMI (kg/m2) | 23.69 ± 3.65 |
| Duration of hospitalization (days) | 12.28 ± 9.47 |
| Duration of antibiotic treatment(days) | 10.43 ± 7.28 |
| Clearance of creatinine (mL/min) | |
| >90 | 54(23.6) |
| 50–89 | 80(34.9) |
| 10–49 | 75(32.8) |
| Hemodialysis | 20(8.7) |
| Pre-existing medical diseases | |
| Cardiovascular diseases | 81(35.3) |
| Diabetes mellitus | 69(30.1) |
| Renal diseases | 26(11.3) |
| Pulmonary diseases | 18(7.8) |
| Cancers | 12(5.2) |
| CNS diseases | 5(2.1) |
| Gastrointestinal | 5(2.1) |
| aOthers | 10(4.3) |
| Wards | |
| Internal medicine | 115(50.2) |
| General surgery | 61(26.7) |
| Internal ICU | 34(14.8) |
| Surgical ICU | 19(8.3) |
Notes: aOthers: psychiatric diseases, acquired immune deficiency syndrome (AIDS), hepatitis B, hepatitis C, rheumatoid arthritis and thyroid disorders.
Abbreviations: SD, standard deviation; BMI, body mass index; CNS, central nervous system.
Figure 2The appropriateness of antimicrobial therapy in different groups of antibiotics.
Note: *Miscellaneous included metronidazole.
Abbreviation: IA, inappropriate administration.
The Appropriateness Of Antimicrobial Therapy In Different Groups Of Antibiotics
| Antibiotic Group | Frequency Of Prescription n (%) | AP Use n (%) | IA Use n (%) | P-Value | OR For IA Use (95% CI) |
|---|---|---|---|---|---|
| Glycopeptides | 66 (13.4) | 21 (31.9) | 45 (68.1) | 0.433 | 0.799 (0.456–1.399) |
| Carbapenems | 78 (15.8) | 2 (2.6) | 76 (97.4) | <0.001 | 18.321 (4.433–75.719) |
| Lincosamides | 54 (11) | 17 (31.5) | 37 (68.5) | 0.521 | 0.819 (0.444–1.509) |
| Cephalosporins | 116 (23.5) | 37 (31.9) | 79 (68.1) | 0.259 | 0.771 (0.490–1.212) |
| Macrolides | 26 (5.2) | 12 (46.2) | 14 (53.8) | 0.036 | 0.426 (0.192–0.947) |
| Fluoroquinolones | 55 (11.1) | 13 (23.7) | 42 (76.3) | 0.467 | 1.276 (0.662–2.458) |
| Penicillins | 21 (4.3) | 2 (9.6) | 19 (90.4) | 0.075 | 3.806 (0.874–16.562) |
| Aminoglycosides | 20 (4.1) | 0 (0) | 20 (100) | 0.998 | NC |
| aMiscellaneous | 57 (11.6) | 33 (57.9) | 24 (42.1) | <0.001 | 0.228 (0.129–0.403) |
| Total | 493 (100) | 137 (27.8) | 356 (72.2) |
Note: aMiscellaneous includes metronidazole.
Abbreviations: AP, appropriate; IA, inappropriate; OR, odds ratio; CI, confidence interval; NC, not calculable.
Adherence To The Guidelines For Antibiotic Therapy In Different Infections
| Infection | Number Of Prescribed Antibiotics | AP Use n (%) | IA Use n (%) | P-value | OR For IA Use (95% CI) |
|---|---|---|---|---|---|
| CAP | 96 | 16 (16.7) | 80 (83.3) | 0.008 | 2.192 (1.230–3.906) |
| Pyelonephritis | 44 | 0 (0) | 44 (100) | 0.998 | NC |
| Sepsis | 73 | 13 (17.8) | 60 (82.2) | 0.042 | 1.933 (1.024–3.649) |
| Septic arthritis | 16 | 7 (43.8) | 9 (56.2) | 0.156 | 0.482 (0.176–1.320) |
| HAP | 25 | 4 (16.0) | 21 (84.0) | 0.186 | 2.084 (0.702–6.187) |
| Meningitis | 4 | 0 (0) | 4 (100) | 0.998 | NC |
| Cellulitis | 16 | 2 (12.5) | 14 (87.5) | 0.183 | 2.763 (0.620–12.321) |
| Cholecystitis | 40 | 11 (27.5) | 29 (72.5) | 0.966 | 1.016 (0.493–2.095) |
| Diabetic foot | 38 | 16 (42.1) | 22 (57.9) | 0.044 | 0.498 (0.253–0.980) |
| SSI | 24 | 12 (50) | 12(50) | 0.016 | 0.363 (0.159–0.830) |
| Abscess | 18 | 7 (38.9) | 11 (61.1) | 0.289 | 0.592 (0.225–1.560) |
| Aspiration pneumonia | 26 | 11 (42.3) | 15 (57.7) | 0.095 | 0.504 (0.225–1.126) |
| Peritonitis | 73 | 38 (52.1) | 35 (47.9) | <0.001 | 0.284 (0.170–0.474) |
| Total | 493 | 137 (27.8) | 356 (72.2) |
Abbreviations: AP, appropriate; IA, inappropriate; OR, odds ratio; CI, confidence interval; NC, not calculable; CAP, community-acquired pneumonia; HAP, hospital-acquired pneumonia; SSI, surgical site infection.
The Appropriateness Of Antimicrobial Therapy In The Evaluated Wards
| Ward | Number Of Prescribed Antibiotics | AP Use n (%) | IA Use n (%) | P-Value | OR For IA Use (95% CI) |
|---|---|---|---|---|---|
| Internal medicine | 241 | 46 (19.1) | 195 (80.9) | <0.001 | 2.396 (1.588–3.616) |
| General surgery | 127 | 60 (47.2) | 67 (52.8) | <0.001 | 0.298 (0.194–0.457) |
| Internal ICU | 82 | 17 (20.7) | 65 (79.3) | 0.120 | 1.577 (0.887–2.801) |
| Surgical ICU | 43 | 14 (32.6) | 29 (67.4) | 0.466 | 0.779 (0.389–1.524) |
| Total | 493 | 137 (27.8) | 356 (72.2) |
Abbreviations: AP, appropriate; IA, inappropriate; OR, odds ratio; CI, confidence interval; NC, not calculable; ICU, intensive care unit.
Comparison Of Antibiotics Administrations Appropriateness, Regarding Various Aspects
| Antibiotics | Frequency Of Administration | Proper Safety n (%) | Appropriate Route Of Administration n (%) | Appropriate Interval n (%) | Appropriate Dose n (%) | Appropriate Duration n (%) | Appropriate Indication n (%) |
|---|---|---|---|---|---|---|---|
| Amikacin | 20 | 4 (20%) | 20 (100%) | 12 (60%) | 17 (85%) | 11 (55%) | 12 (60%) |
| Ampicillin-sulbactam | 7 | 6 (85.7%) | 7 (100%) | 3 (42.9%) | 7 (100%) | 4 (57.1%) | 3 (42.9%) |
| Azithromycin | 26 | 26 (100%) | 26 (100%) | 25 (96.2%) | 16 (61.5%) | 22 (84.6%) | 26 (100%) |
| Cefepime | 7 | 6 (85.7%) | 7 (100%) | 2 (28.6%) | 7 (100%) | 6 (85.7%) | 7 (100%) |
| Ceftazidim | 6 | 5 (83.3%) | 6 (100%) | 3 (50%) | 5 (83.3%) | 6 (100%) | 6 (100%) |
| Ceftriaxone | 103 | 103 (100%) | 103 (100%) | 44 (42.7%) | 97 (94.2%) | 82 (79.6%) | 98 (95.1%) |
| Ciprofloxacin | 56 | 41 (73.2%) | 45 (80.4%) | 41 (73.2%) | 47 (83.9%) | 38 (67.9%) | 44 (78.6%) |
| Clindamycin | 55 | 55 (100%) | 53 (96.4%) | 52 (94.5%) | 53 (96.4%) | 35 (63.6%) | 32 (58.2%) |
| Cloxacillin | 8 | 8 (100%) | 8 (100%) | 4 (50%) | 2 (25%) | 7 (85.7%) | 5 (62.5%) |
| Imipenem | 62 | 0 (0%) | 62 (100%) | 40 (64.5%) | 35 (56.5%) | 34 (54.8%) | 55 (88.7%) |
| Meropenem | 16 | 11 (68.75%) | 16 (100%) | 7 (43.8%) | 12 (75%) | 12 (75%) | 13 (81.3%) |
| Metronidazole | 57 | 57 (100%) | 56 (98.2%) | 57 (100%) | 57 (100%) | 47 (82.5%) | 39 (68.4%) |
| Piperacillin-tazobactam | 6 | 6 (100%) | 6 (100%) | 5 (83.3%) | 3 (50%) | 4 (66.7%) | 3 (50%) |
| Vancomycin | 67 | 57 (85.07) | 67 (100%) | 45 (67.2%) | 63 (94%) | 42 (62.7%) | 57 (85.1%) |
| Total | 496 | 385 (77.62%) | 482 (97.18%) | 340 (68.54%) | 421 (84.88%) | 350 (70.56%) | 400 (80.64%) |
Figure 3Performing culture and modifying antibiotic regimens according to the culture results.
Antibiotic administrations in DDD/100 patients/Day
| Antibiotic | DDD/100 Patients/Day |
|---|---|
| Amikacin | 1.958 |
| Ampicillin-sulbactam | 11.272 |
| Azithromycin (oral) | 8.945 |
| Cefepime | 1.286 |
| Ceftazidime | 0.613 |
| Ceftriaxone | 98.692 |
| Ciprofloxacin (parenteral) | 2.149 |
| Clindamycin (parenteral) | 19.375 |
| Cloxacillin (PO) | 6.653 |
| Imipenem | 15.77 |
| Meropenem | 14.999 |
| Metronidazole | 31.259 |
| Piperacillin-tazobactam | 1.373 |
| Vancomycin | 34.22 |
| Total | 248.56 |
Total Costs And Waste Costs For Each Antibiotic
| Antibiotic | DDD/100 Patients/Day | Total Cost (IRR) | Total Cost ($) | IA (%) | Waste Cost (IRR) | Waste Cost ($) |
|---|---|---|---|---|---|---|
| Amikacin | 1.958 | 27,708,000 | 659.71 | 100 | 27,708,000 | 659.71 |
| Ampicillin-sulbactam | 11.272 | 624,368,000 | 14,865.90 | 85.7 | 535,083,376 | 12,740.08 |
| Azithromycin | 8.945 | 31,318,000 | 745.67 | 53.8 | 16,849,084 | 401.17 |
| Cefepime | 1.286 | 139,664,000 | 3,325.33 | 85.7 | 119,692,048 | 2,849.81 |
| Ceftazidime | 0.613 | 38,325,000 | 912.5 | 66.7 | 25,562,775 | 608.64 |
| Ceftriaxone | 98.692 | 2,056,650,000 | 48,967.86 | 67 | 1,377,955,500 | 32,808.46 |
| Ciprofloxacin (Parenteral) | 2.149 | 5,065,068,000 | 120,596.86 | 76.3 | 3,864,646,884 | 92,015.40 |
| Clindamycin | 19.375 | 1,266,680,800 | 30,159.07 | 68.5 | 867,676,348 | 20,658.96 |
| Cloxacillin | 6.653 | 210,748,000 | 5,017.81 | 87.5 | 184,404,500 | 4,390.58 |
| Imipenem | 15.77 | 5,785,120,000 | 137,740.95 | 100 | 5,785,120,000 | 137,740.95 |
| Meropenem | 14.999 | 5,063,850,000 | 120,567.86 | 87.5 | 4,430,868,750 | 105,496.87 |
| Metronidazole | 31.259 | 927,660,000 | 22,087.14 | 42.1 | 390,544,860 | 9,298.69 |
| Piperacillin-tazobactam | 1.373 | 227,035,000 | 5,405.59 | 100 | 227,035,000 | 5,405.59 |
| Vancomycin | 34.22 | 2,852,100,000 | 534,836.25 | 68.1 | 1,942,280,100 | 46,244.76 |
| Total | 24,316,294,800 | 578,959.39 | 19,795,427,225 | 471,319.69 |
Culture Practice Rates In Different Wards
| Wards | Need The Culture To Be Performed | Culture Performed | Culture Was Not Performed | P-value |
|---|---|---|---|---|
| Internal ICU | 81 | 63 (77.8%) | 18 (22.2%) | <0.001 |
| Internal medicine | 223 | 44 (19.7%) | 179 (80.3%) | |
| Surgical ICU | 36 | 5 (13.9%) | 31 (86.1%) | |
| Surgery | 96 | 12 (12.5%) | 84 (87.5%) | |
| 436 | 124 (28.4%) | 312 (71.6%) |